drugset / Trial / NCT01016145

Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm

NCT01016145

Phase 4 Unknown 126 enrolled University of Sao Paulo
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate predictors of response to antipsychotic medication in subjects with schizophrenia. The investigators will evaluate psychopathology,brain MRI, genetics and neuropsychological profile. Two groups of treatment will be compared: first generation antipsychotics vs. second generation antipsychotics. Participants will be randomized to one of the groups. Trial duration: 12 weeks.

Timeline

Start
2009-04
Primary completion
2010-06
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 15 mg
Subject Aripiprazole Other / unclassified 30 mg
Subject Chlorpromazine Small molecule 25 mg
Subject Chlorpromazine Small molecule 600 mg
Subject Haloperidol Other / unclassified 2.5 mg
Subject Haloperidol Other / unclassified 10 mg
Subject Olanzapine Small molecule 5 mg
Subject Olanzapine Small molecule 20 mg
Subject Quetiapine Small molecule 25 mg
Subject Quetiapine Small molecule 800 mg
Subject Risperidone Other / unclassified 2 mg
Subject Risperidone Other / unclassified 8 mg
Subject Ziprasidone Small molecule 80 mg
Subject Ziprasidone Small molecule 160 mg

Indications